Journal
DIABETES RESEARCH AND CLINICAL PRACTICE
Volume 102, Issue 1, Pages E8-E12Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.diabres.2013.07.010
Keywords
DPP-4; CD26; DPP-4 inhibitors; Polyarthropathy; SDF-1 alpha
Categories
Funding
- Grants-in-Aid for Scientific Research [21679005, 24659401] Funding Source: KAKEN
Ask authors/readers for more resources
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) inhibit the inactivation of incretin hormones while also affecting the immune system, since CD26/DPP-4 is involved in immune regulation. The current study shows that the use of DPP-4Is as therapy for type 2 diabetes patients may induce joint symptoms with decrease in plasma SDF-1 alpha level. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
